Meeting
2018 Genitourinary Cancers Symposium
Tivozanib combined with nivolumab: Phase Ib/II study in metastatic renal cell carcinoma (mRCC).
Authors
Bernard Escudier
Gustave Roussy Cancer Campus, Villejuif, France
Bernard Escudier , Philippe Barthelemy , Alain Ravaud , Sylvie Negrier , Michael N. Needle , Laurence Albiges
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Clinical Trial Registration Number
NCT03136627
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 618)
DOI
10.1200/JCO.2018.36.6_suppl.618
Abstract #
618
Poster Bd #
G11
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Nephrectomy after complete response to immune checkpoint inhibitors for metastatic renal cell carcinoma (mRCC): A new surgical challenge?
First Author: Geraldine Pignot
Poster
2018 Genitourinary Cancers Symposium
Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC): Results from the NIVOREN GETUG-AFU 26 study.
First Author: Laurence Albiges
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Single agent and combination checkpoint inhibitors therapy: A post marketing safety analysis.
First Author: Rawad Elias
Poster
2017 ASCO Annual Meeting
The safety and early efficacy of high-dose ipilimumab (IPI) and the combination nivolumab plus ipilimumab (NIVO + IPI) in patients (pts) with uveal melanoma (UM).
First Author: Sapna Pradyuman Patel